KPV
Aliases: α-MSH(11-13) · Lys-Pro-Val
Last verified: 2026-09-23
The short version
The C-terminal tripeptide of α-MSH — retains anti-inflammatory properties without pigmentation. Popular for IBD, SIBO and inflammatory gut/skin conditions. Key fact: Human data are limited: small trials or case-series reports exist, without large randomized studies. Preclinical IBD models show reduced colon inflammation; dermatology studies for wounds/psoriasis. Status: research chemical. Not approved; available as research chemical and via compounding pharmacies.
Identity & type
- Molecular type
- peptide
- Origin
- The C-terminal tripeptide of α-MSH — retains anti-inflammatory properties without pigmentation.
Mechanism of action
Enters cells via the PepT1 transporter, inhibits NF-κB and MAPK inflammatory pathways, reduces IL-8/TNF-α.
not confirmed in humans
Dosing & routes
Official / clinical context
No approved official document exists for KPV. Any protocols mentioned are to be read as information, not as a recommendation.
Regulator-approved labeling and published study designs — never a recommendation.
Community-reported practice
Orally 250–500 mcg 1–2× daily for gut; SC 200–500 mcg; topically for skin/wounds. The community reports calming of IBD/Crohn's symptoms, skin inflammation (psoriasis, eczema) and a mild general anti-inflammatory tone; popular both orally and topically.
Unverified self-reports. Not medical advice. Not endorsement.
Expected effects (community)
The community reports calming of IBD/Crohn's symptoms, skin inflammation (psoriasis, eczema) and a mild general anti-inflammatory tone; popular both orally and topically.
Protocol — official vs community
Official / label
No approved product. Alpha-MSH fragment (Lys-Pro-Val) studied in inflammatory models; human data thin.
Duration: Study use only.
The anti-inflammatory tail of the melanocortin system without the pigmentation.
Community (anecdotal)
Oral capsules (200–600 mcg) or 100–300 mcg SC daily for gut/inflammation protocols.
- Cycle:
- 4–8 weeks.
- Break:
- 4 weeks.
Oral-first routing is the community norm — unusual and sensible for a peptide with gut-indication anecdotes.
Human evidence
Human data are limited: small trials or case-series reports exist, without large randomized studies. Preclinical IBD models show reduced colon inflammation; dermatology studies for wounds/psoriasis.
Preclinical evidence
Preclinical IBD models show reduced colon inflammation; dermatology studies for wounds/psoriasis.
Known risks
- Very mild; rare GI upset.characterized
- Unregulated injectable supply — sterility, purity and accurate dose not assuredtheoretical
Teal: characterized in clinical/labeling contexts. Amber: theoretical or reported outside controlled settings.
Unknowns & evidence gaps
- Long-term human safety
- Optimal dose and pharmacokinetics
Frequently asked questions
References
Systematic references are being expanded; verify sources directly before any decision.